These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

866 related items for PubMed ID: 11224490

  • 1. In vitro measurement of platelet glycoprotein IIb/IIIa receptor blockade by abciximab: interindividual variation and increased platelet secretion.
    Rossi F, Rossi E, Pareti FI, Colli S, Tremoli E, Gallo L.
    Haematologica; 2001 Feb; 86(2):192-8. PubMed ID: 11224490
    [Abstract] [Full Text] [Related]

  • 2. Incomplete inhibition of platelet aggregation and glycoprotein IIb-IIIa receptor blockade by abciximab: importance of internal pool of glycoprotein IIb-IIIa receptors.
    Gawaz M, Ruf A, Pogatsa-Murray G, Dickfeld T, Rüdiger S, Taubitz W, Fischer J, Müller I, Meier D, Patscheke H, Schömig A.
    Thromb Haemost; 2000 Jun; 83(6):915-22. PubMed ID: 10896249
    [Abstract] [Full Text] [Related]

  • 3. Occupancy of the internal and external pools of glycoprotein IIb/IIIa following abciximab bolus and infusion.
    Quinn MJ, Murphy RT, Dooley M, Foley JB, Fitzgerald DJ.
    J Pharmacol Exp Ther; 2001 May; 297(2):496-500. PubMed ID: 11303035
    [Abstract] [Full Text] [Related]

  • 4. Effect of glycoprotein IIb-IIIa receptor antagonism on platelet membrane glycoproteins after coronary stent placement.
    Gawaz M, Ruf A, Neumann FJ, Pogátsa-Murray G, Dickfeld T, Zohlnhöfer D, Schömig A.
    Thromb Haemost; 1998 Dec; 80(6):994-1001. PubMed ID: 9869173
    [Abstract] [Full Text] [Related]

  • 5. Glycoprotein IIb/IIIa and P2Y12 receptor antagonists yield additive inhibition of platelet aggregation, granule secretion, soluble CD40L release and procoagulant responses.
    Judge HM, Buckland RJ, Holgate CE, Storey RF.
    Platelets; 2005 Nov; 16(7):398-407. PubMed ID: 16236601
    [Abstract] [Full Text] [Related]

  • 6. Paradoxical inhibition of fibrinogen binding and potentiation of alpha-granule release by specific types of inhibitors of glycoprotein IIb-IIIa.
    Schneider DJ, Taatjes DJ, Sobel BE.
    Cardiovasc Res; 2000 Jan 14; 45(2):437-46. PubMed ID: 10728364
    [Abstract] [Full Text] [Related]

  • 7. Augmentation of inhibitory effects of glycoprotein IIb-IIIa antagonists in patients with diabetes.
    Keating FK, Whitaker DA, Sobel BE, Schneider DJ.
    Thromb Res; 2004 Jan 14; 113(1):27-34. PubMed ID: 15081562
    [Abstract] [Full Text] [Related]

  • 8. Glycoprotein IIb/IIIa inhibition enhances platelet nitric oxide release.
    Chakrabarti S, Clutton P, Varghese S, Cox D, Mascelli MA, Freedman JE.
    Thromb Res; 2004 Jan 14; 113(3-4):225-33. PubMed ID: 15140587
    [Abstract] [Full Text] [Related]

  • 9. In vitro efficacy of platelet glycoprotein IIb/IIIa antagonist in blocking platelet function in plasma of patients with heparin-induced thrombocytopenia.
    Mak KH, Kottke-Marchant K, Brooks LM, Topol EJ.
    Thromb Haemost; 1998 Dec 14; 80(6):989-93. PubMed ID: 9869172
    [Abstract] [Full Text] [Related]

  • 10. The GP IIb/IIIa inhibitor abciximab (ReoPro) decreases activation and interaction of platelets and leukocytes during in vitro cardiopulmonary bypass simulation.
    Straub A, Wendel HP, Azevedo R, Ziemer G.
    Eur J Cardiothorac Surg; 2005 Apr 14; 27(4):617-21. PubMed ID: 15784360
    [Abstract] [Full Text] [Related]

  • 11. An additional mechanism of action of abciximab: dispersal of newly formed platelet aggregates.
    Marciniak SJ, Mascelli MA, Furman MI, Michelson AD, Jakubowski JA, Jordan RE, Marchese PJ, Frelinger AL.
    Thromb Haemost; 2002 Jun 14; 87(6):1020-5. PubMed ID: 12083481
    [Abstract] [Full Text] [Related]

  • 12. Upregulation of GP IIb/IIIa receptors during platelet activation: influence on efficacy of receptor blockade.
    Matzdorff A, Voss R.
    Thromb Res; 2006 Jun 14; 117(3):307-14. PubMed ID: 15894353
    [Abstract] [Full Text] [Related]

  • 13. Comparative studies of a humanized anti-glycoprotein IIb/IIIa monoclonal antibody, YM337, and abciximab on in vitro antiplatelet effect and binding properties.
    Suzuki K, Sato K, Kamohara M, Kaku S, Kawasaki T, Yano S, Iizumi Y.
    Biol Pharm Bull; 2002 Aug 14; 25(8):1006-12. PubMed ID: 12186399
    [Abstract] [Full Text] [Related]

  • 14. P2Y12 receptor blockade augments glycoprotein IIb-IIIa antagonist inhibition of platelet activation, aggregation, and procoagulant activity.
    Berny-Lang MA, Jakubowski JA, Sugidachi A, Barnard MR, Michelson AD, Frelinger AL.
    J Am Heart Assoc; 2013 May 15; 2(3):e000026. PubMed ID: 23676293
    [Abstract] [Full Text] [Related]

  • 15. Quantifying GPIIb/IIIa receptor binding using 2 monoclonal antibodies: discriminating abciximab and small molecular weight antagonists.
    Quinn M, Deering A, Stewart M, Cox D, Foley B, Fitzgerald D.
    Circulation; 1999 May 04; 99(17):2231-8. PubMed ID: 10226086
    [Abstract] [Full Text] [Related]

  • 16. Quantification of abciximab-induced platelet inhibition is assay dependent: a comparative study in patients undergoing percutaneous coronary intervention.
    Furman MI, Kereiakes DJ, Krueger LA, Mueller MN, Broderick TM, Schneider JF, Howard WL, Fox ML, Barnard MR, Frelinger AL, Michelson AD.
    Am Heart J; 2003 Feb 04; 145(2):e6. PubMed ID: 12595861
    [Abstract] [Full Text] [Related]

  • 17. Ex vivo--in vitro interaction between aspirin, clopidogrel, and the glycoprotein IIb/IIIa inhibitors abciximab and SR121566A.
    Klinkhardt U, Kirchmaier CM, Westrup D, Graff J, Mahnel R, Breddin HK, Harder S.
    Clin Pharmacol Ther; 2000 Mar 04; 67(3):305-13. PubMed ID: 10741635
    [Abstract] [Full Text] [Related]

  • 18. Effect of glycoprotein IIb/IIIa antagonist abciximab on monocyte-platelet aggregates and tissue factor expression.
    Steiner S, Seidinger D, Huber K, Kaun C, Minar E, Kopp CW.
    Arterioscler Thromb Vasc Biol; 2003 Sep 01; 23(9):1697-702. PubMed ID: 12869353
    [Abstract] [Full Text] [Related]

  • 19. Comparative in vitro efficacy of different platelet glycoprotein IIb/IIIa antagonists on platelet-mediated clot strength induced by tissue factor with use of thromboelastography: differentiation among glycoprotein IIb/IIIa antagonists.
    Mousa SA, Khurana S, Forsythe MS.
    Arterioscler Thromb Vasc Biol; 2000 Apr 01; 20(4):1162-7. PubMed ID: 10764688
    [Abstract] [Full Text] [Related]

  • 20. Paradoxical platelet activation was not observed on dissociation of abciximab from GpIIb-IIIa complexes.
    Ndoko S, Poujol C, Combrié R, Nurden A, Nurden P.
    Thromb Haemost; 2002 Feb 01; 87(2):317-22. PubMed ID: 11858493
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 44.